Lake Street Capital Issues Pessimistic Forecast for MDxHealth (NASDAQ:MDXH) Stock Price

MDxHealth (NASDAQ:MDXH) had its price target lowered by investment analysts at Lake Street Capital from $9.00 to $5.00 in a report issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Lake Street Capital’s price objective would indicate a potential upside of 407.77% from the stock’s previous close.

Several other brokerages have also commented on MDXH. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MDxHealth in a research report on Friday, March 27th. TD Cowen reaffirmed a “buy” rating and set a $1.50 price target (down from $7.00) on shares of MDxHealth in a research report on Thursday. William Blair lowered shares of MDxHealth from an “outperform” rating to a “market perform” rating in a research report on Thursday. Finally, BTIG Research dropped their price target on shares of MDxHealth from $7.00 to $4.00 and set a “buy” rating for the company in a research report on Thursday. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $4.63.

MDxHealth Stock Down 49.5%

Shares of NASDAQ:MDXH traded down $0.97 during trading on Thursday, reaching $0.98. The stock had a trading volume of 10,868,031 shares, compared to its average volume of 297,605. The business has a fifty day moving average price of $2.52 and a 200-day moving average price of $3.27. The stock has a market cap of $48.74 million, a P/E ratio of -1.47 and a beta of 1.60. MDxHealth has a fifty-two week low of $0.94 and a fifty-two week high of $5.33.

MDxHealth (NASDAQ:MDXH) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). MDxHealth had a negative net margin of 31.07% and a negative return on equity of 1,078.01%. The firm had revenue of $23.90 million during the quarter, compared to analyst estimates of $30.89 million. As a group, equities analysts forecast that MDxHealth will post -0.41 EPS for the current year.

Institutional Investors Weigh In On MDxHealth

Several large investors have recently made changes to their positions in MDXH. Kennedy Capital Management LLC acquired a new stake in shares of MDxHealth in the third quarter worth $1,826,000. Marshall Wace LLP acquired a new stake in shares of MDxHealth in the fourth quarter worth $609,000. Mink Brook Asset Management LLC acquired a new stake in shares of MDxHealth in the third quarter worth $743,000. Panoramic Capital LLC acquired a new stake in shares of MDxHealth in the third quarter worth $721,000. Finally, FreeGulliver LLC increased its position in shares of MDxHealth by 104.7% in the third quarter. FreeGulliver LLC now owns 252,894 shares of the company’s stock worth $1,176,000 after acquiring an additional 129,348 shares in the last quarter.

MDxHealth News Roundup

Here are the key news stories impacting MDxHealth this week:

• Positive Sentiment: BTIG Research kept a Buy rating on MDxHealth, even while cutting its price target to $4.00 from $7.00, implying upside from current levels. BTIG price target update
• Neutral Sentiment: The company’s Q1 2026 earnings call transcript and highlights were published, giving investors more detail on management’s commentary and strategic priorities. Q1 2026 earnings highlights
• Neutral Sentiment: MDxHealth also released its full Q1 2026 results and conference call materials, which may help investors gauge execution and the company’s revenue trajectory. Q1 2026 results transcript
• Negative Sentiment: William Blair downgraded MDxHealth from Outperform to Market Perform, signaling reduced conviction in the near-term outlook. William Blair downgrade
• Negative Sentiment: Q1 2026 results missed expectations, with EPS of -$0.19 versus -$0.14 expected and revenue of $23.9 million versus $30.9 million expected, increasing concern about growth and profitability. Earnings miss details
• Negative Sentiment: Management’s FY2026 revenue guidance of $110 million to $115 million came in below the consensus estimate of $122.6 million, which likely added pressure to the stock. FY2026 guidance

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.